Antibody Discovery and Optimization
Antibodies are highly precise and versatile molecules that help the immune system find and eliminate viruses, bacteria, and even cancer cells. Their enormous potential in therapeutics and diagnostics relies on their ability to bind targets with high specificity and be manufactured efficiently at scale. These are the most critical early stages of the drug development pipeline, where quickly securing the right antibody candidates can save years of development time and millions of dollars downstream.
Recent breakthroughs in artificial intelligence, from large language models to protein structure prediction, have enabled in silico antibody design and optimization, dramatically accelerating drug development so patients can access life-saving treatments faster.
Our End-to-End In Silico Solution
AbXLr8 is our platform that transforms raw sequencing data from your phage or yeast display experiments into a curated set of binders optimized for both binding affinity and developability.
Key Capabilities
Deep Library Exploration
- Comprehensive analysis of sequence and structural diversity across your antibody library
- Identification of candidates with optimal affinity and developability profiles
- Unbiased assessment of the full candidate landscape
AI-enhanced Design
- Generation of novel antibody sequences jointly optimized for affinity and developability
- Machine learning models that leverage sequence, structure, and surface information
- Predictive screening to prioritize candidates with the highest probability of clinical success
Our solution combines deep characterization of antibody libraries with cutting-edge machine learning and AI to enhance and accelerate your drug development pipeline, reducing experimental cycles and de-risking downstream development.
Integrated Workflow
Personalized Solutions for Your Project
Whether you're entering antibody discovery and development for the first time or looking to enhance an existing program, we provide end-to-end support tailored to your specific needs:
- Hit Discovery - Identify promising candidates from complex libraries
- Sequence and Structure Modeling - Detailed characterization of binding modes and epitopes
- AI-Based Predictive Screening - Rank candidates by predicted clinical success
- Lead Optimization - Refine existing candidates or generate novel candidates for affinity, specificity, and developability
We work closely with you to build a bespoke workflow matching your requirements for:
- Antibody modalities (monoclonal antibodies, bispecifics, ADCs, nanobodies)
- Timeline and resource constraints
Accelerate Your Path to the Clinic
Let us provide the catalytic in silico solution that can:
- Accelerate your drug development workflow
- De-risk clinical progression
- Optimize resource allocation
- Deliver the right set of candidates to advance to IND-enabling studies
Partner with us to accelerate how you discover and develop your antibodies.
La nostra sede
Nexco Analytics Bâtiment Alanine Route de la Corniche 5B 1066 Epalinges, Svizzera
Chiamaci
+41 76 509 73 73
Lasciaci un messaggio
contact@nexco.chNon esitare a contattarci
Ti risponderemo a breve con la soluzione ottimale per le tue esigenze
© 2024 Nexco Analytics. All Rights Reserved.